Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Protara Therapeutics, Inc. (TARA)

$4.02 -0.50% NASDAQ: TARA · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: TARA
  • 51 employees
$225.9MMarket cap
$2.9MRevenue · FY2014
-$57.4MNet income
51Employees
TARANASDAQ
2020IPO

About Protara Therapeutics, Inc.

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2014
$2.9M
Net income
-$57.4M
Total assets
$209.5M
Market cap
$225.9M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$64.5M
Operating income
-$64.5M
Income tax
-$11.0M
Net income
-$57.4M
EPS (basic)
$-1.34
EPS (diluted)
$-1.34

Balance sheet

Total assets
$209.5M
Current assets
$159.5M
Total liabilities
$13.1M
Current liabilities
$10.9M
Shareholders’ equity
$196.4M

Cash flow

Operating cash flow
-$56.4M
Investing cash flow
-$139.5M
Financing cash flow
$82.7M
Net cash flow
-$113.1M

Statements via Polygon.io (SEC filings)

NASDAQ: TARA
$4.02 -0.50%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.78 $7.56

52-week range

Market cap
$225.9M
EPS (diluted)
$-1.34
Shares outstanding
58.2M
Open
Day range
Prev close
Volume
IPO date
Jan 10, 2020

Protara Therapeutics, Inc. (TARA) Stock Price

  • Reported a net loss of $57.4M in FY2014.
  • Trading 47% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Protara Therapeutics, Inc..

Write a review
Newsroom

News about Protara Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Protara Therapeutics, Inc.: frequently asked questions

Is Protara Therapeutics, Inc. an American company?

Protara Therapeutics, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Protara Therapeutics, Inc. headquartered?

Protara Therapeutics, Inc. is headquartered in New York, New York, United States.

Is Protara Therapeutics, Inc. publicly traded?

Yes — Protara Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TARA on the NASDAQ.

What does Protara Therapeutics, Inc. do?

Protara Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →